JPRN-UMIN000004331已完成2 期
Safety and efficacy of preoperative chemotherapy with SOX+Cetuximab in patients with liver-only metastases(H2,H3), KRAS-WT from colorectal cancer(KSCC1002) - Safety and efficacy of preoperative chemotherapy with SOX+Cetuximab in patients with liver-only metastases(H2,H3), KRAS-WT from colorectal cancer(KSCC1002)
Kyushu Study group of Clinical Cancer0 个研究点目标入组 32 人开始时间: 2010年10月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Prior liver or pulmonary resection. 2.Administering antithrombotic drug within 7 days. 3.History of serious drug hypersensitivity or a history of drug allergy 4.Peripheral neuropathy 5.Active other malignancies. 6.Active infection. 7.Serious complications (renal failure or hepatic failure) 8.High blood pressure and diabetic and hypercalcemia that cannot be controlled 9.symptomatic or asymptomatic but treated heart disease 10.interstitial pnumonitis, pulmonary fibrosis or high-grade pulmonary emphysema 11.histry of mental disturbances, central nervous system disorder or cerebrovascular attack 12.Fresh hemorrhage from digestive tube, intestines tube paralysis, intestinal obstruction and peptic ulcer 13.Pleural effusion peritoneal fluid and pericardial fluid 14.Symptomatic brain metastasis 15.Watery stools or diarrhea 16.under continuous steroid therapy 17.Requiring flucytosine, phenytoin, Warfarin Potassium. 18.Infection with hepatitis B or C virus 19.Pregnant or lactating woman 20.No birth-control 21.Not appropriate for the study at the physician's assessment
研究者
相似试验
已完成
2 期
Safety and efficacy of preoperative chemotherapy with mFOLFOX6+Bevacizumab in patients with liver-only metastases (H2, H3) from colorectal cancer; histological assessment of liver damage from preoperative chemotherapy.Patients with liver-only metastases from colorectal cancerJPRN-UMIN000001308Kyushu Study group of Clinical Cancer39
尚未招募
不适用
A phase II trial of preoperative chemotherapy with capecitabine plus short-course radiotherapy for resectable T3 rectal cancerJPRN-UMIN000016518Meiwa Hospital60
招募中
不适用
Feasibility study of perioperative chemotherapy with neoadjuvant GEM+CDDP and adjuvant S-1 for biliary tract cancerBiliary tract cancerJPRN-UMIN000021206Keio University School of Medicine30
已完成
不适用
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility multicenter study(1) breast cancer with histological confirmation(2) stage II or III breast cancer and previous standard anthracycline and/or taxane-based PSC, followed by curative surgery(3) age 20-75 years(4) Eastern Cooperative Oncology Group performance status 0,1(5) adequate gastrointestinal function(6) adequate organ functionJPRN-UMIN000013469Saitama Medical University International Medical Center40
已完成
2 期
Efficacy and safety of neoadjuvant chemotherapy by S-1 plus cisplatin for Stage III esophageal squamous cell carcinoma: A phase II trialEsophageal squamous cell carcinomaJPRN-UMIN000014707agoya University Hospital30